Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin.

The drug retention and circulation lifetime properties of liposomal nanoparticles (LN) containing dihydrosphingomyelin (DHSM) have been investigated. It is shown that replacement of egg sphingomyelin (ESM) by DHSM in sphingomyelin/cholesterol (Chol) (55/45; mol/mol) LN results in substantially improved drug retention properties both in vitro and in vivo. In the case of liposomal formulations of vincristine, for example, the half-times for drug release (T(1/2)) were approximately 3-fold longer for DHSM/Chol LN as compared to ESM/Chol LN, both in vitro and in vivo. Further increases in T(1/2) could be achieved by increasing the drug-to-lipid ratio of the liposomal vincristine formulations. In addition, DHSM/Chol LN also exhibit improved circulation lifetimes in vivo as compared to ESM/Chol LN. For example, the half-time for LN clearance (Tc(1/2)) at a low lipid dose (15 micromol lipid/kg, corresponding to 8 mg lipid/kg body weight) in mice was 3.8 h for ESM/Chol LN compared to 6 h for DHSM/Chol LN. In addition, it is also shown that DHSM/Chol LN exhibit much longer half-times for vincristine release as compared to LN with the "Stealth" lipid composition. It is anticipated that DHSM/Chol LN will prove useful as drug delivery vehicles due to their excellent drug retention and circulation lifetime properties.

[1]  D. Vance,et al.  Biochemistry of Lipids and Membranes , 1985 .

[2]  J. Slotte,et al.  Analysis of natural and synthetic sphingomyelins using high-performance thin-layer chromatography. , 1999, European journal of biochemistry.

[3]  M. Woodle,et al.  Long Circulating Liposomes: Old Drugs, New Therapeutics , 1998, Biotechnology Intelligence Unit.

[4]  K. Edwards,et al.  An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[5]  M. Bally,et al.  Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. , 1997, The Journal of pharmacology and experimental therapeutics.

[6]  P. Cullis,et al.  Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.

[7]  P. Cullis,et al.  Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. , 1998, Biochimica et biophysica acta.

[8]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[9]  M. Bally,et al.  Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin , 2004, Cancer Chemotherapy and Pharmacology.

[10]  Y. Oh,et al.  Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection , 1995, Antimicrobial agents and chemotherapy.

[11]  J. Slotte,et al.  Membrane properties of D-erythro-N-acyl sphingomyelins and their corresponding dihydro species. , 2001, Biophysical journal.

[12]  A. J. Clifford,et al.  BIOCHIMICA ET BIOPHYSICA ACTA , 2022 .

[13]  P. Cullis,et al.  Influence of dose on liposome clearance: critical role of blood proteins. , 1996, Biochimica et biophysica acta.

[14]  M. Bally,et al.  Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. , 1985, Biochimica et biophysica acta.

[15]  M. Bally,et al.  Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.

[16]  M. Bally,et al.  Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia , 2004, Cancer Chemotherapy and Pharmacology.

[17]  A. Gabizon.  Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. , 1992, Cancer research.

[18]  M. Bally,et al.  Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. , 1990, Cancer research.

[19]  C. H. Fiske,et al.  THE COLORIMETRIC DETERMINATION OF PHOSPHORUS , 1925 .

[20]  D. Borchman,et al.  Separation and characterization of the unknown phospholipid in human lens membranes. , 1994, Investigative ophthalmology & visual science.

[21]  P. Cullis,et al.  Influence of cholesterol on the association of plasma proteins with liposomes. , 1996, Biochemistry.

[22]  L. Mayer,et al.  Optimization of the retention properties of vincristine in liposomal systems. , 1993, Biochimica et biophysica acta.

[23]  M. Johnston,et al.  Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. , 2006, Biochimica et biophysica acta.

[24]  E. P. Kennedy,et al.  Metabolism of labeled dihydrosphingomyelin in vivo. , 1968, Journal of lipid research.

[25]  T. Tadakuma,et al.  Temperature-sensitive release of adriamycin, an amphiphilic antitumor agent, from dipalmitoylphosphatidylcholine-cholesterol liposomes. , 1989, Biochimica et biophysica acta.

[26]  A. Spector,et al.  Membrane cholesterol and phospholipid in consecutive concentric sections of human lenses. , 1985, Journal of lipid research.

[27]  K. Edwards,et al.  Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. , 2005, Journal of pharmaceutical sciences.

[28]  F. Dosio,et al.  From Conventional to Stealth Liposomes a new Frontier in Cancer Chemotherapy , 2003, Tumori.

[29]  M. Bally,et al.  Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. , 1998, Biochimica et biophysica acta.

[30]  G Gregoriadis,et al.  Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. , 1991, Biochimica et biophysica acta.

[31]  M. Bally,et al.  Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. , 1995, British Journal of Cancer.

[32]  S. Zellmer,et al.  Tumor targeting in vivo by means of thermolabile fusogenic liposomes. , 1996, Journal of drug targeting.

[33]  F. Goebel,et al.  Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. , 1998, European journal of medical research.

[34]  L. Mayer,et al.  Vesicles of variable sizes produced by a rapid extrusion procedure. , 1986, Biochimica et biophysica acta.

[35]  C. Leonetti,et al.  In vivo administration of liposomal vincristine sensitizes drug‐resistant human solid tumors , 2004, International journal of cancer.

[36]  G. Hahn,et al.  Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumor efficacy. , 1994, International journal of radiation oncology, biology, physics.

[37]  P. Cullis,et al.  Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. , 1998, Advanced drug delivery reviews.

[38]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[39]  P. Cullis,et al.  Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study. , 1998, Biochimica et biophysica acta.

[40]  T. Allen,et al.  Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.

[41]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.